BioMarin Pharmaceutical Inc. Stock News

If approved, Valrox could become the most expensive drug in the world.

BioMarin (BMRN) is set to initiate dosing in an early-stage clinical study in the first quarter to evaluate its gene therapy candidate, BMN 307, in phenylketonuria, a rare disease affecting the brain.

Fast-approaching catalysts could make these biotech stocks top performers this year.

BioMarin (BMRN) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

With 2020 now rolling, and the first quarter in full swing, many investors are resetting for what could be a more volatile rest of the year as the ongoing trade issues and geopolitical instability in

BioMarin (BMRN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

BioMarin (BMRN) submits a BLA in the United States for its investigational gene therapy valoctocogene roxaparvovec to treat adult patients with severe hemophilia A.

Shares of BioMarin Pharmaceutical Inc. BMRN, +2.17% are up 2.8% in morning trading on Monday following positive clinical findings from a Phase 3 trial for achondroplasia.

Gene therapy continues to draw attention with the recent spate of deals and acquisitions. We list four stocks with promising candidates in their pipelines that make attractive acquisition targets.

The business reported a handful of positive developments.

REGN vs. BMRN: Which Stock Is the Better Value Option?

Here are four stocks that boast promising prospects and are most likely to be takeout targets.

BioMarin (BMRN) submits an MAA in Europe for its investigational gene therapy valoctocogene roxaparvovec to treat adult patients with severe hemophilia A.

BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock?

BioMarin Pharmaceutical CEO Jean-Jacques Bienaimé chats with Jim Cramer about the impact of the recent FDA approval the company received for its hemophilia drug.